Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Haemophilia

• Publication date

  2006-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1365-2516.2005.01170.xPMID 16409170
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rituximab in the treatment of acquired factor VIII inhibitors

  2006cited by this paper
• Rituximab: expanding role in therapy for lymphomas and autoimmune diseases.

  2004cited by this paper
• Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia

  2004cited by this paper
• Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia.

  2004cited by this paper
• Life-Threatening Bleeding from Refractory Acquired FVIII Inhibitor Successfully Treated with Rituximab

  2003cited by this paper
• Acquired high-titer factor VIII inhibitor: fatal bleeding despite multimodal treatment including rituximab preceded by multiple plasmaphereses.

  2003cited by this paper
• Rituximab for the treatment of refractory autoimmune hemolytic anemia in children.

  2003cited by this paper
• Pediatric Hodgkin's disease--up, up, and beyond.

  2002cited by this paper
• Rituximab in the treatment of acquired factor VIII inhibitors.

  2002cited by this paper
• Rituximab: clinical development and future directions

  2002cited by this paper
• The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism.

  2002cited by this paper
• Rituximab for refractory childhood autoimmune hemolytic anemia.

  2002cited by this paper
• Rituximab: an anti-CD20 antibody for the treatment of chronic refractory immune thrombocytopenic purpura.

  2002cited by this paper
• Comparative pharmacokinetic studies in haemophilia

  2002cited by this paper
• Is high expression of the chemokine receptor cxcr‐4 of predictive value for early relapse in childhood acute lymphoblastic leukaemia?

  2002cited by this paper
• B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.

  2002cited by this paper
• Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome.

  2002cited by this paper
• Treatment of relapsed idiopathic thrombocytopenic purpura with the anti‐CD20 monoclonal antibody rituximab: a pilot study

  2002cited by this paper
• Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab.

  2001cited by this paper
• Successful treatment of high titer inhibitors in mild hemophilia A with avoidance of factor VIII and immunosuppressive therapy

  2001cited by this paper
• Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.

  2001cited by this paper
• Treatment of childhood autoimmune haemolytic anaemia with rituximab.

  2001cited by this paper
• Refractory autoimmune thrombocytopenic purpura treatment with Rituximab

  2001cited by this paper
• Successful treatment of an Epstein-Barr virus-associated B-cell lymphoproliferative disease in a child with acute lymphoblastic leukemia using an anti-CD20 monoclonal antibody.

  2001cited by this paper
• Sustained remission of platelet counts following monoclonal anti‐CD20 antibody therapy in two cases of idiopathic autoimmune thrombocytopenia
and neutropenia

  2001cited by this paper
• Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab.

  2000cited by this paper
• Properties of Anti-Factor VIII Inhibitor Antibodies in Hemophilia A Patients

  2000cited by this paper
• The German National Immune Tolerance Registry, 1997 update. Study Group of German Haemophilia Centres.

  1999cited by this paper
• Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance.

  1999cited by this paper
• Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation.

  1999cited by this paper
• Clinical applications of anti-CD20 antibodies.

  1999cited by this paper
• The German National Immune Tolerance Registry, 1997 Update

  1999cited by this paper
• Analysis of the North American Immune Tolerance Registry (NAITR) 1993–1997: Current Practice Implications

  1999cited by this paper
• Analysis of the North American Immune Tolerance Registry (NAITR) 1993-1997: current practice implications. ISTH Factor VIII/IX Subcommittee Members.

  1999cited by this paper
• Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

  1998cited by this paper
• Factor VIII Inhibitors in Mild and Moderate-severity Haemophilia A

  1998cited by this paper
• Factor VIII inhibitors in mild and moderate‐severity haemophilia A

  1998cited by this paper
• Immune tolerance: a synopsis of the international experience

  1998cited by this paper
• The International Registry of Immune Tolerance: 1994 Update

  1996cited by this paper
• Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

  1994cited by this paper
• Immune Tolerance in Hemophilia-Principal Results from the International Registry

  1994cited by this paper
• Recombinant Factor VIII for the Treatment of Previously Untreated Patients with Hemophilia A: Safety, Efficacy, and Development of Inhibitors

  1993cited by this paper
• Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group.

  1993cited by this paper
• Human B lymphocytes: phenotype, proliferation, and differentiation.

  1992cited by this paper
• Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs.

  1992cited by this paper
• Factor VIII inhibitor in mild haemophilia.

  1986cited by this paper
• Characterization and properties of an inhibitor of factor 8 in the plasma of patients with hemophilia A following repeated transfusions.

  1967cited by this paper

• Efficacy and Safety of Rituximab as Frontline Therapy for Eradication of Inhibitors in Congenital Haemophilia A

  2025cites this paper
• Outcomes of ITI with rituximab to eradicate high-titer inhibitor of hemophilia A depicted by exponential decay model and the gene expression profile of different outcomes by RNA-Seq.

  2025cites this paper
• The efficacy of the rituximab-containing rescue-regimen for severe hemophilia A inhibitor children who relapsed following successful immune tolerance induction with rituximab in China.

  2023cites this paper
• The efficacy of sequential MMF-rescue-regimen to eradicate inhibitors for refractory severe hemophilia A inhibitor children in China.

  2023cites this paper
• Oral tolerance to prevent anti-drug antibody formation in protein replacement therapies.

  2022cites this paper
• Low‐dose immune tolerance induction alone or with immunosuppressants according to prognostic risk factors in Chinese children with hemophilia A inhibitors

  2021cites this paper
• Factor VIII-Fc Activates Natural Killer Cells via Fc-Mediated Interactions With CD16

  2021cites this paper
• Clinical Care of Bone Health in Patients on the Immune Tolerance Induction’s Protocols With an Immunosuppressive Agent for Inhibitor Eradication in Hemophilia

  2020cites this paper
• A low‐dose immune tolerance induction (ITI) protocol incorporating immunosuppressive agents in haemophilia A children with high‐titre factor VIII inhibitor and poor‐ITI prognostic risk

  2020cites this paper
• B Cell Depletion Eliminates FVIII Memory B Cells and Enhances AAV8-coF8 Immune Tolerance Induction When Combined With Rapamycin

  2020cites this paper
• Recombinant Factor VIII Fc Inhibits B Cell Activation via Engagement of the FcγRIIB Receptor

  2020cites this paper
• Rituximab for treating inhibitors in people with inherited severe hemophilia.

  2020cites this paper
• Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult‐to‐treat patients

  2018cites this paper
• Dexamethasone promotes durable factor VIII-specific tolerance in hemophilia A mice via thymic mechanisms

  2018cites this paper
• Rituximab for treating inhibitors in people with inherited severe hemophilia.

  2017cites this paper
• Factor VIII inhibitors: Advances in basic and translational science

  2017cites this paper
• Innovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A

  2017cites this paper
• Refractory lupus nephropathy and acquired Factor VIII and IX deficiencies in a patient with systemic lupus erythematosus treated with rituximab

  2017cites this paper
• Marginal zone B cells are critical to factor VIII inhibitor formation in mice with hemophilia A.

  2017cites this paper
• Co-Infection of the Hepatitis C Virus With Other Blood-Borne and Hepatotropic Viruses Among Hemophilia Patients in Poland

  2016cites this paper
• Inhibitors in Severe Hemophilia A: 25-Year Experience in Slovakia

  2016cites this paper
• Current view and outcome of ITI therapy - A change over time?

  2016cites this paper
• War and peace: Factor VIII and the adaptive immune response.

  2016cites this paper
• Combination therapy for inhibitor reversal in haemophilia A using monoclonal anti-CD20 and rapamycin

  2016cites this paper
• The use of intravenous immunoglobulin in immune tolerance induction in inherited haemophilia A: a single-centre experience and a review of literature

  2015cites this paper
• Exposure of FVIII in the Presence of Phosphatidyl Serine Reduces Generation of Memory B-Cells and Induces Regulatory T-Cell-Mediated Hyporesponsiveness in Hemophilia A Mice.

  2015cites this paper
• Rituximab for treating inhibitors in people with inherited severe hemophilia.

  2015cites this paper
• The Use of Rituximab with Immune Tolerance Induction Therapy for Hemophilia A with Inhibitors

  2015cites this paper
• Hemofilije u djece

  2014cites this paper
• SVEUČILIŠTE U ZAGREBU MEDICINSKI FAKULTET

  2014cites this paper
• treatment in mild hemophilia A Molecular and clinical predictors of inhibitor risk and its prevention and

  2014cites this paper
• Inhibitors – genetic and environmental factors

  2014cites this paper
• Anti-CD20 as the B-Cell Targeting Agent in a Combined Therapy to Modulate Anti-Factor VIII Immune Responses in Hemophilia a Inhibitor Mice

  2014cites this paper
• Molecular and clinical predictors of inhibitor risk and its prevention and treatment in mild hemophilia A.

  2014cites this paper
• Inhibitor eradication with rituximab in haemophilia: where do we stand?

  2014cites this paper
• Rituximab for treatment of inhibitors in haemophilia A

  2014cites this paper
• Rituximab as first‐line treatment for the management of adult patients with non‐severe hemophilia A and inhibitors

  2014cites this paper
• Immunosuppressive agents in the treatment of inhibitors in congenital haemophilia A and B – a systematic literature review

  2014cites this paper
• Successful urgent neurosugery management with rFVIIa mega doses in a child with haemophilia A and high titre inhibitor.

  2014cites this paper
• Immune tolerance induction for treating inhibitors in people with congenital haemophilia A or B.

  2014cites this paper
• Primary and rescue immune tolerance induction in children and adults: a multicentre international study with a VWF‐containing plasma‐derived FVIII concentrate

  2014cites this paper
• Long-term treatment course of a patient with mild haemophilia A who developed a high titre factor VIII inhibitor

  2014cites this paper
• Role of B Cells in Breaking and Maintaining Tolerance to Clotting Factor VIII in Congenital and Acquired Hemophilia A

  2014cites this paper
• Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition)

  2013cites this paper
• The Reversal of Inhibitors in Congenital Hemophilia

  2013cites this paper
• Identical but different: haemophilia B in monozygotic twins with inhibitor in one brother and subsequent successful immune tolerance induction

  2012cites this paper
• Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease

  2012cites this paper
• Animal models of hemophilia.

  2012cites this paper
• A review of current methods for assessing hemostasis in vivo and introduction to a potential alternative approach.

  2012cites this paper
• Immune tolerance induction in patients with severe hemophilia with inhibitors: expert panel views and recommendations for clinical practice

  2012cites this paper
• Co-morbidity in adult haemophilia patients

  2012cites this paper
• Hemophilic Treatment for Procedures

  2012cites this paper
• Immune Tolerance Induction Programs

  2011cites this paper
• The use of a single von Willebrand factor‐containing, plasma‐derived FVIII product in hemophilia A immune tolerance induction: the US experience

  2011cites this paper
• What is the evidence for the use of immunomodulatory agents to eradicate inhibitory antibodies in patients with severe hemophilia a who have previously failed to respond to immune tolerance induction?

  2011cites this paper
• The etiology of inhibitor development in children with severe hemophilia A

  2011cites this paper
• Effect of B-cell depletion using anti-CD20 therapy on inhibitory antibody formation to human FVIII in hemophilia A mice.

  2011cites this paper
• Advances in hemophilia: experimental aspects and therapy.

  2010cites this paper
• Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence‐based approaches

  2010cites this paper
• Immunomodulation for inhibitors in hemophilia A: the important role of Treg cells

  2010cites this paper
• Mild haemophilia: a disease with many faces and many unexpected pitfalls

  2010cites this paper
• Induction of immune tolerance using rituximab in a child with severe haemophilia B with inhibitors and anaphylaxis to factor IX

  2010cites this paper
• Clinical issues in inhibitors

  2010cites this paper
• Gene therapy for tolerance and vice versa: a case for hemophilia.

  2010cites this paper
• Inhibitor treatment by rituximabin congenital haemophilia A

  2009cites this paper
• Elevation of B cell-activating factor belonging to the tumour necrosis factor [corrected] family (BAFF) in haemophilia A patients with inhibitor.

  2009cites this paper
• Multimerization of Peptide Mimotopes for Blocking of Factor VIII Neutralizing Antibodies

  2009cites this paper
• A review of the current use of rituximab in autoimmune diseases.

  2009cites this paper
• Recent Improvements in the Clinical Treatment of Coagulation Factor Inhibitors

  2009cites this paper
• Factor VIII Inhibitors: Risk Factors and Methods for Prevention and Immune Modulation

  2009cites this paper
• Immuntoleranztherapie mit Rituximab bei Patienten mit angeborener Hämophilie A und Inhibitorbildung – zwei Fallberichte

  2009cites this paper
• Side‐effects and venous access issues with immune tolerance therapy

  2009cites this paper
• Rituximab as a single agent in the management of adult patients with haemophilia A and inhibitors: marked reduction in inhibitor level and clinical improvement in bleeding but failure to eradicate the inhibitor

  2009cites this paper
• Elevation of B cell-activating factor belonging to the tumour necrosis family family (BAFF) in haemophilia A patients with inhibitor

  2009cites this paper
• Case 38-2008

  2009cites this paper
• Rituximab and immune tolerance in severe hemophilia A: a consecutive national cohort

  2009cites this paper
• Orthopaedic surgery in haemophilia patients with inhibitors: a practical guide to haemostatic, surgical and rehabilitative care

  2009cites this paper
• Co‐morbidity in the ageing haemophilia patient: the down side of increased life expectancy

  2009cites this paper
• Discordant antibody response in monozygotic twins with severe haemophilia A caused by intensive treatment

  2009cites this paper
• Advances in hemophilia: experimental aspects and therapy.

  2008cites this paper
• Case records of the Massachusetts General Hospital. Case 38-2008. A 58-year-old man with hemophilia, hepatocellular carcinoma, and intractable bleeding.

  2008cites this paper
• Inhibitors in mild/moderate haemophilia A: two case reports and a literature review.

  2008cites this paper
• Mild/moderate haemophilia A: new insights into molecular mechanisms and inhibitor development

  2008cites this paper
• Rituximab and desensitization for a patient with severe factor IX deficiency, inhibitors, and history of anaphylaxis.

  2008cites this paper
• Prophylaxis with recombinant factor VIIa for the management of bleeding episodes during immune tolerance treatment in a boy with severe haemophilia A and high‐response inhibitors

  2008cites this paper
• Immune tolerance with rituximab in congenital haemophilia with inhibitors: a systematic literature review based on individual patients’ analysis

  2008cites this paper
• Humoral immune responsiveness to a defined epitope on factor VIII before and after B cell ablation with rituximab.

  2008cites this paper
• Immune tolerance induction for the eradication of inhibitors in patients with hemophilia A

  2008cites this paper
• Synthesis and Secretion of Coagulation Factor VIII

  2008cites this paper
• Haemophilia EDITED BY

  2007cites this paper
• Inhibitors to Factor VIII—Mild and Moderate Hemophilia

  2007cites this paper
• Rituximab for the treatment of childhood chronic idiopathic thrombocytopenic purpura and hemophilia with inhibitors

  2007cites this paper
• Inhibitors in haemophilia A: current management and open issues

  2007cites this paper
• Haemophilia therapies

  2007cites this paper
• International workshop on immune tolerance induction: consensus recommendations 1

  2007cites this paper
• Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors

  2007cites this paper
• The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation

  2006cites this paper
• Intracellular delivery of purine nucleoside phosphorylase (PNP) fused to protein transduction domain corrects PNP deficiency in vitro.

  2006cites this paper
• The role of immunomodulation in the management of factor VIII inhibitors.

  2006cites this paper
• The efficacy of rituximab in the treatment of inhibitor-associated hemostatic disorders

  2006cites this paper